Tirofiban

• CAS: 144494-65-5
• Catalog Number: ACM144494655
• Category: Main Products
• Molecular Weight: 440.6
• Molecular Formula: C₂₂H₃₆N₂O₅S
• Synonyms: TIROFIBAN;(2s)-2-(butylsulfonylamino)-3-[4-[4-(4-piperidyl)butoxy]phenyl]propanoic acid;Aggrastat;MK-383;N-(Butylsulfonyl)-O-[4-(4-piperidinyl)butyl]-L-tyrosine;C07965;Tirofiban/Tirofiban HCl;irofiban
• IUPAC Name: (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoicacid
• Canonical SMILES: CCCCS(=O)(=O)NC(CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O
• InChI Key: COKMIXFXJJXBQG-NRFANRHFSA-N
• Boiling Point: 611.7ºC at 760mmHg
• Melting Point: 223-225ºC
• Flash Point: 323.7ºC
• Density: 1.154g/cm³
• Exact Mass: 440.23400
• Hazard Statements: Xi
• Safety Description: 26
• Supplemental Hazard Statements: H315-H319-H335
• Symbol: GHS07

Case Study

Safety and Efficacy Evaluation of Tirofiban in the Treatment of STEMI

Dannenberg, Lisa, et al. International Journal of Cardiology, 2019, 274, 35-39.

To investigate the efficacy and safety of tirofiban in patients with ST-segment elevation myocardial infarction (STEMI), this work evaluated and analyzed MACCE (death, myocardial infarction [MI], stroke) and TIMI bleeding events during hospitalization and 12 months of follow-up in 610 STEMI patients.
Results:
· Patients receiving tirofiban were slightly younger, with an average age of 63 ± 13 years compared to 65 ± 14 years in the control group (p = 0.04). This group also exhibited higher peak levels of high-sensitive troponin T (Hs-TnT), showing results of 6561 ± 11,065 in the tirofiban group versus 4594 ± 11,200 in the control group (p = 0.047), alongside higher peak-creatine kinase (CK) levels, with the tirofiban group at 2742 ± 5097 and the control group at 1416 ± 2160 (p < 0.0001).
· It was more difficult to perform the percutaneous coronary intervention (PCI) on patients with tirofiban due to the greater exposure to radiation (18 ± 15 minutes for tirofiban vs. 14 ± 13 minutes for control; p = 0.02) and use of contrast agents (240 ± 106 for tirofiban vs. 209 ± 99 for control; p = 0.01).
· Nonetheless, there were no significant differences observed in major adverse cardiovascular and cerebrovascular events (MACCE) (HR 0.877, 95% CI 0.62-1.25, p = 0.47) or in bleeding complications, with major bleeding having an HR of 1.494 (95% CI 0.65-3.44, p = 0.34) and minor bleeding at HR 1.294 (95% CI 0.67-2.52, p = 0.45).

Meta-Analysis of Tirofiban for Acute Ischemic Stroke

Gong, Jinhong, et al. European Journal of Clinical Pharmacology, 2020, 76, 475-481.

Tirofiban is a highly selective, rapid-acting non-peptide glycoprotein IIb/IIIa (Gp IIb/IIIa) platelet receptor antagonist with a short half-life. As there is no consensus on the clinical use of tirofiban in patients with acute ischemic stroke (AIS), this paper aims to conduct a meta-analysis of cohort studies to compare the safety and efficacy of tirofiban versus non-tirofiban regimens in the treatment of AIS.
Findings
· Seventeen studies involving 2,914 patients with acute ischemic stroke (AIS) were analyzed. The combined results indicated that treatment with tirofiban did not elevate the risk of symptomatic intracerebral hemorrhage (sICH) (odds ratio [OR], 0.95; 95% confidence interval [CI], 0.71-1.28; p = 0.75) or mortality (OR, 0.80; 95% CI, 0.64-1.02; p = 0.07).
· Nonetheless, there was a significant increase in fatal intracerebral hemorrhage within the tirofiban group (OR, 2.84; 95% CI, 1.38-5.85; p = 0.005). Subgroup analyses revealed that tirofiban administered via intra-arterial (IA) route was linked to a higher risk of fatal intracerebral hemorrhage (OR, 2.90; 95% CI, 1.12-7.55; p = 0.03), whereas intravenous (IV) administration did not show this association (OR, 2.75; 95% CI, 0.92-8.20; p = 0.07).
· Overall, tirofiban seems to be a safe option for systemic therapy and may be viable for treating AIS. However, intra-arterial use necessitates additional well-designed studies to establish a suitable protocol.

Custom Q&A

What is the molecular formula of tirofiban?

The molecular formula of tirofiban is C22H36N2O5S.

What is the molecular weight of tirofiban?

The molecular weight of tirofiban is 440.6 g/mol.

What is the role of tirofiban as a drug?

Tirofiban has a role as a fibrin modulating drug, a platelet glycoprotein-IIb/IIIa receptor antagonist, and an anticoagulant.

What is the IUPAC name of tirofiban?

The IUPAC name of tirofiban is (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid.

What is the InChIKey of tirofiban?

The InChIKey of tirofiban is COKMIXFXJJXBQG-NRFANRHFSA-N.

How does tirofiban prevent blood clotting?

Tirofiban prevents blood clotting by acting as a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, which inhibits platelet aggregation.

What is the CAS number of tirofiban?

The CAS number of tirofiban is 144494-65-5.

What are the synonyms of tirofiban?

The synonyms of tirofiban include Aggrastat, 144494-65-5, tirofibanum, and Agrastat.

Is tirofiban a Platelet Aggregation Inhibitor?

Yes, tirofiban is a Platelet Aggregation Inhibitor.

What is the common name of tirofiban hydrochloride?

The common name of tirofiban hydrochloride is 142373-60-2.